News & Updates

Pembrolizumab + chemo emerging as first-line SoC in advanced oesophageal cancer

05 Oct 2020 by

Pembrolizumab in combination with chemotherapy significantly improves overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) vs chemotherapy alone in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer, according to results of the phase III KEYNOTE-590 study presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Pembrolizumab + chemo emerging as first-line SoC in advanced oesophageal cancer

05 Oct 2020

Serum assessment detects nonadherence to adjuvant tamoxifen in early breast cancer

05 Oct 2020 by

Serum assessment of drug level may detect early nonadherence to adjuvant tamoxifen therapy and identify patients with early breast cancer at risk of poorer outcomes, new data from the CANTO study have shown.

Serum assessment detects nonadherence to adjuvant tamoxifen in early breast cancer

05 Oct 2020

Obesity not a reason for aggressive levofloxacin dosing for febrile neutropaenia prophylaxis

04 Oct 2020

Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.

Obesity not a reason for aggressive levofloxacin dosing for febrile neutropaenia prophylaxis

04 Oct 2020

Radiotherapy with concurrent docetaxel beneficial in seniors with oesophageal cancer

02 Oct 2020

Radiotherapy with concurrent docetaxel is safe and effective in elderly patients with oesophageal cancer, regardless of baseline renal function, according to a study.

Radiotherapy with concurrent docetaxel beneficial in seniors with oesophageal cancer

02 Oct 2020

Unmarried patients face shorter survival, later stage at diagnosis of cutaneous melanoma

02 Oct 2020

More advanced stages of cutaneous melanoma are usually diagnosed among unmarried patients, especially men and those younger than 68 years of age, even in visible sites such as the face, according to a US study. In addition, these patients have worse survival independent of stage.

Unmarried patients face shorter survival, later stage at diagnosis of cutaneous melanoma

02 Oct 2020

Paclitaxel-carboplatin an adjuvant chemo alternative for women with operable TNBC

02 Oct 2020 by

A paclitaxel-carboplatin (PCb) regimen may be an alternative adjuvant chemotherapeutic strategy for women with operable triple-negative breast cancer (TNBC), given its greater benefit over a conventional regimen comprising cyclophosphamide, epirubicin, and fluorouracil, followed by docetaxel (CEF-T), the phase III PATTERN* trial has shown.

Paclitaxel-carboplatin an adjuvant chemo alternative for women with operable TNBC

02 Oct 2020

BNP helps diagnose malignant mesothelioma

01 Oct 2020

The ratio of pleural fluid to blood B-type natriuretic peptide (BNP), which is secreted from malignant mesothelial cells, can aid in the diagnosis of malignant mesothelioma, suggests a recent study.

BNP helps diagnose malignant mesothelioma

01 Oct 2020

New blood test for head, neck cancer in the works

01 Oct 2020 by

A blood serum microRNA biomarker signature for oropharyngeal squamous cell carcinoma was recently reported in the Journal of Translational Medicine. The researchers involved in its discovery are expanding on this finding to develop a blood test model that will help predict or diagnose head and neck cancers. [Available at https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02446-1 Accessed on 14 September 2020]

New blood test for head, neck cancer in the works

01 Oct 2020

Spironolactone does not up risk of breast cancer recurrence

30 Sep 2020

Use of spironolactone does not increase the risk of female breast cancer recurrence and may be considered for the treatment of alopecia in survivors, results of a recent study have shown.

Spironolactone does not up risk of breast cancer recurrence

30 Sep 2020

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

29 Sep 2020 by

The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate 238 trial presented at ESMO 2020.

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

29 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Pembrolizumab + chemo emerging as first-line SoC in advanced oesophageal cancer

Pembrolizumab + chemo emerging as first-line SoC in advanced oesophageal cancer

Serum assessment detects nonadherence to adjuvant tamoxifen in early breast cancer

Serum assessment detects nonadherence to adjuvant tamoxifen in early breast cancer

Obesity not a reason for aggressive levofloxacin dosing for febrile neutropaenia prophylaxis

Obesity not a reason for aggressive levofloxacin dosing for febrile neutropaenia prophylaxis

Radiotherapy with concurrent docetaxel beneficial in seniors with oesophageal cancer

Radiotherapy with concurrent docetaxel beneficial in seniors with oesophageal cancer

Unmarried patients face shorter survival, later stage at diagnosis of cutaneous melanoma

Unmarried patients face shorter survival, later stage at diagnosis of cutaneous melanoma

Paclitaxel-carboplatin an adjuvant chemo alternative for women with operable TNBC

Paclitaxel-carboplatin an adjuvant chemo alternative for women with operable TNBC

BNP helps diagnose malignant mesothelioma

BNP helps diagnose malignant mesothelioma

New blood test for head, neck cancer in the works

New blood test for head, neck cancer in the works

Spironolactone does not up risk of breast cancer recurrence

Spironolactone does not up risk of breast cancer recurrence

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma